Activation of cytotoxic T cells by solid tumours?

Cellular and Molecular Life Sciences

Volumn 54, Issue 3, 1998, Pages 263-271

  Speiser, D E ^a   Ohashi, P S ^b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Acute autoimmunity; Chronic autoimmune disease; CTL; Immunotherapy; Tumour antigen; Tumour immunogenicity

Indexed keywords

TUMOR ANTIGEN;

ANTIGEN PRESENTATION; CYTOTOXIC T LYMPHOCYTE; HUMAN; IMMUNIZATION; LYMPH FOLLICLE; LYMPHOCYTE ACTIVATION; LYMPHOID TISSUE; REVIEW; SOLID TUMOR; TUMOR IMMUNOLOGY;

ANIMALS; ANTIGENS, NEOPLASM; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; LYMPHOCYTE ACTIVATION; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0031980506     PISSN: 1420682X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s000180050148     Document Type: Review

References (103)

1. Gartner H. V., Seidl C., Luckenbach C., Schumm G., Seifried E., Ritter H. et al. (1996) Genetic analysis of a sarcoma accidentally transplanted from a patient to a surgeon. N. Engl. J. Med. 334: 1494-1496
2. Houghton A. N. (1995) On course for a cancer vaccine. Lancet 345: 1384-1385
3. Zinkernagel R. M. and Doherty P. C. (1974) Restriction of in vitro T cell mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system. Nature 248: 701-702
4. Townsend A. R. M., Rothbard J., Gotch F. M., Bahadur G., Wraith D. and McMichael A. J. (1986) The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell 44: 959-968
5. Maryanski J. L., Pala P., Corradin G., Jordan B. R. and Cerottini J.-C. (1986) H-2 restricted cytolytic T cells specific for HLA can recognize a synthetic HLA peptide. Nature 324: 578-579
6. Moore M. W., Carbone F. R. and Bevan M. J. (1988) Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell 54: 777-785
7. d by cytolytic T cells. Cell 58: 293-303
8. Houghton A. N. (1994) Cancer antigens: immune recognition of self and altered self. J. Exp. Med. 180: 1-4
9. Van Pel A., van der Bruggen P., Coulie P. G., Briehard V. G., Lethe B., Van den Eynde B. et al. (1995) Genes coding for tumor antigens recognized by cytolytic T lymphocytes. Immunol. Rev. 145: 229-250
10. Kawakami Y., Eliyahu S., Delgaldo C. H., Robbins P. F., Rivoltini L., Topalian S. L. et al. (1994) Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc. Natl. Acad. Sci. USA 91: 3515-3519
11. Kawakami Y., Eliyahu S., Delgado C. H., Robbins P. F., Sakaguchi K., Appella E. et al. (1994) Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc. Natl. Acad. Sci. USA 91: 6458-6462
12. Brichard V., Van Pel A., Wolfel T., Wolfer C., De Plaen E., Lethe B. et al. (1997) The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 178: 489-495
13. Robbins P. F., El-Gamil M., Kawakami Y. and Rosenberg S. A. (1994) Recognition of tyrosinase by tumor infiltrating lymphocytes from a patient responding to immunotherapy. Cancer Res. 54: 3124-3126
14. Wang R. F., Robbins P. F., Kawakami Y., Kang X. Q. and Rosenberg S. A. (1995) Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31 restricted tumor-infiltrating lymphocytes. J. Exp. Med. 181: 799-804
15. Wang R. F., Appella F., Kawakami Y., Kang X. and Rosenberg S. A. (1996) Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J. Exp. Med. 184: 2207-2216
16. Bloom M. B., Perry-Lalley D., Robbins P. F., Li Y., El-Gamil M., Rosenberg S. A. et al. (1997) Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J. Exp. Med. 185: 453-459
17. Ressing M. E., van Driel W. J., Celis E., Sette A., Brandt R. M. P., Hartman M. et al. (1996) Occasional memory cytotoxic T-cell responses of patients with human papillomavirus type 16-positive cervical lesions against a human leukocyte antigen-A*0201-restricted E7-encoded epitope. Cancer Res. 56: 582-588
18. Peoples G. E., Goedegebuure P. S., Smith R., Linehan D. C., Yoshino I. and Eberlein T. J. (1995) Breast and ovarian cancer-specific T lymphocytes recognize the same HER2/neu-derived peptide. Proc. Natl. Acad. Sci. USA 92: 432-436
19. Theobald M., Biggs J., Dittmer D., Levine A. J. and Sherman L. A. (1995) Targeting p53 as a general tumor antigen. Proc. Natl. Acad. Sci. USA 92: 11993-11997
20. van der Bruggen P., Traversari C., Chomez P., Lurquin C., DePlaen E., Van den Eynde B. et al. (1991) A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254: 1643-1647
21. Gaugler B., Van den Eynde B., van der Bruggen P., Romero P., Gaforio J. J., DePlaen E. et al. (1994) Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J. Exp. Med. 179: 921-930
22. Boel P., Wildmann C., Sensi M. L., Brasseir R., Renauld J.-C., Coulie P. et al. (1995) BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity 2: 167-175
23. Van den Eynde B., Peeters O., De Backer O., Gaugler B., Lucas S. and Boon T. (1995) A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J. Exp. Med. 182: 689-698
24. Guilloux Y., Lucas S., Brichard V. G., Van Pel A., Viret C., De Plaen E. et al. (1996) A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N-acetylglucosaminyltransferase V gene. J. Exp. Med. 183: 1173-1183
25. Van den Eynde B., Lethe B., Van Pel A., De Plaen E. and Boon T. (1991) The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice. J. Exp. Med. 173: 1373-1384
26. Robbins P. F., El-Gamil M., Li Y. F., Kawakami Y., Loftus D., Appella E. et al. (1996) A mutated β-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J. Exp. Med. 183: 1185-1192
27. Coulie P. G., Lehmann F., Lethe B., Herman J., Lurquin C., Andrawiss M. et al. (1995) A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc. Natl. Acad. Sci. USA 92: 7976-7980
28. INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269: 1281-1284
29. Mandruzzato S., Brasseur F., Andry G., Boon T. and van der Bruggen P. (1997) A CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma. J. Exp. Med. 186: 785-793
30. Mandelboim O., Berke G., Fridkin M., Feldman M., Eisenstein M. and Eisenbach L. (1994) CTL induction by a tumour-associated antigen octapeptide derived from a murine lung carcinoma. Nature 369: 67-71
31. Noguchi Y., Chen Y. T. and Old L. J. (1994) A mouse mutant p53 product recognized by CD4+ and CD8+ T cells. Proc. Natl. Acad. Sci. USA 91: 3171-3175
32. Cerottini J. C., Lienard D. and Romero P. (1996) Recognition of tumor associated antigens by T-lymphocytes: perspectives for peptide-based vaccines. Ann. Oncol. 7: 339-342
33. Romero P. (1996) Cytolytic T lymphocyte responses of cancer patients to tumor-associated antigens. Springer Semin. Immunopathol. 18: 185-198
34. Rosenberg S. A., Kawakami Y., Robbins P. F. and Wang R. (1996) Identification of the genes encoding cancer antigens: implications for cancer immunotherapy. Adv. Cancer Res. 70: 145-177
35. Rosenberg S. A. (1997) Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol. Today 18: 175-182
36. Cohen E. P. and Kim T. S. (1994) Neoplastic cells that express low levels of MHC class 1 determinants escape host immunity. Semin. Cancer Biol. 5: 419-428
37. Cromme F. V., Airey J., Heemels M.-T., Ploegh H. L., Keating P. J., Stern P. L. et al. (1994) Loss of transporter protein, encoded by the TAP-1 gene is highly correlated with loss of HLA expression in cervical carcinomas. J. Exp. Med. 179: 335-340
38. Ye X., McCarrick J., Jewett L. and Knowles B. B. (1994) Timely immunization subverts the development of peripheral nonresponsiveness and suppresses tumor development in simian virus 40 tumor antigen-transgenic mice. Proc. Natl. Acad. Sci. USA 91: 3916-3920
39. Garrido F., Ruiz-Cabello F., Cabrera T., Perez-Villar J. J., Lopez-Botet M., Duggan-Keen M. et al. (1997) Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol. Today 18: 89-95
40. Onrust S. V., Hartl P. M., Rosen S. D. and Hanahan D. (1946) Modulation of L-selectin ligand expression during an immune response accompanying tumorigenesis in transgenic mice. J. Clin. Invest. 97: 54-64
41. Boon T. and Kellermann O. (1977) Rejection by syngeneic mice of cell variants obtained by mutagenesis of a malignant teratocarcinoma cell line. Proc. Natl. Acad. Sci. USA 74: 272-275
42. Boon T. and Van Pel A. (1978) Teratocarcinoma cell variants rejected by syngeneic mice: protection of mice immunized with these variants against other variants and against the original malignant cell line. Proc. Natl. Acad. Sci. USA 75: 1519-1523
43. Chen L., Ashe S., Brady W. A., Hellström I., Hellström K. E., Ledbetter J. A. et al. (1992) Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71: 1093-1102
44. Townsend S. E. and Allison J. P. (1993) Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science 259: 368-370
45. Huang A. Y. C., Bruce A. T., Pardoll D. M. and Levitsky H. I. (1996) Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo. J. Exp. Med. 183: 769-776
46. Hellström K. E., Hellström I. and Chen L. (1994) Can co-stimulated tumor immunity be therapeutically efficacious? Immunol. Rev. 145: 123-145
47. Zinkernagel R. M., Callahan G. N., Althage A., Cooper S., Streilein J. W. and Klein J. J. (1978) The lymphoreticular system in triggering virus-plus-self-specific cytotoxic T cells: evidence for T help. J. Exp. Med. 147: 897-911
48. von Boehmer H. and Haas W. (1979) Distinct Ir genes for helper and killer cells in the cytotoxic response to H-Y antigen. J. Exp. Med. 150: 1134-1142
49. Keene J.-A. and Forman J. (1982) Helper activity is required for the in vivo generation of cytotoxic T lymphocytes. J. Exp. Med. 155: 768
50. Fearon E. R., Pardoll D. M., Itaya T., Golumbek P., Levitsky H. I., Simons J. W. et al. (1990) Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 60: 397-403
51. Förster I., Hirose R., Arbeit J. M., Clausen B. E. and Hanahan D. (1995) Limited capacity for tolerization of CD4+ T cells specific for a pancreatic β cell neo-antigen. Immunity 2: 573-585
52. Förster I. and Lieberam I. (1996) Peripheral tolerance of CD4 T cells following local activation in adolescent mice. Eur. J. Immunol. 26: 3194-3202
53. Leung K. H. (1989) Inhibition of human NK cell and LAK cell cytotoxicity and differentiation by prostaglandin E2. Cell. Immunol. 123: 384-388
54. Bodmer S., Huber D., Heid I. and Fontana A. (1991) Human glioblastoma cell derived transforming growth factor-beta 2: evidence for secretion of both high and low molecular weight biologically active forms. J. Neuroimmunol. 34: 33-38
55. Chang H. L., Gillett N., Figari I., Lopez A. R., Palladino M. A. and Derynck R. (1993) Increased transforming growth factor beta expression inhibits cell proliferation in vitro yet increases tumorigenicity and tumor growth of Meth A sarcoma cells. Cancer Res. 53: 4391-4396
56. Arteaga C. L., Hurd S. D., Winnier A. R., Johnson M. D., Fendly B. M. and Forbes J. T. (1993) Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorgenicity and increase mouse spleen natural killer cell activity: implications for a possible role of tumor cell host TGF-beta interactions in human breast cancer progression. J. Clin. Invest. 92: 2569-2574
57. Chen Q., Daniel V., Maher D. W. and Hersey P. (1994) Production of IL-10 by melanoma cells: examination of its role in immunosuppression. Int. J. Cancer 56: 755-759
58. Hahne M., Rimoldi D., Schröter M., Romero P., Schreier M., French L. E. et al. (1996) Melanoma cell expression of Fas(Apo-1/CD95) Ligand: implications for tumor immune escape. Science 274: 1363-1366
59. Walker P. R., Saas P. and Dietrich P.-Y. (1997) Role of Fas ligand (CD95L) in immune escape. The tumor cell strikes back. J. Immunol. 158: 4521-4524
60. Cantor M. and Boyse E. (1977) Contemporary Topics in Immunobiology, Plenum. New York
61. Klein G. (1975) Immunological surveillance against neoplasia. Harvey Lectures (New York) 69: 71-102
62. Prehn R. T. and Main J. M. (19571 Immunity to methylcholanthrene-induced sarcomas. J. Natl. Cancer Inst. 18: 769-782
63. Kündig T. M., Bachmann M. F., DiPaolo C., Simard J. J. L., Battegay M., Lother H. et al. (1995) Fibroblasts as efficient antigen-presenting cells in lymphoid tissues. Science 268: 1343-1347
64. Adams T. E., Alpert S. and Hanahan D. (1987) Non-tolerance and autoantibodies to a transgenic self antigen expressed in pancreatic β cells. Nature 325: 223-228
65. Miller J. F. A. P. and Basten A. (1996) Mechanisms of tolerance to self. Curr. Opin. Immunol. 8: 815-821
66. Kurts C., Heath W. R., Carbone F. R., Allison J., Miller J. F. A. P. and Kosaka H. (1996) Constitutive class I-restricted exogenous presentation oi self antigens in vivo. J. Exp. Med. 184: 923-930
67. Hammerling G. J., Schoenrich G., Ferber I. and Arnold B. (1993) Peripheral tolerance as a multi-step mechanism. Immunol. Rev. 133: 93-104
68. Ohashi P. S., Hengartner H., Battegay M., Zinkernagel R. M. and Pircher H. (1994) In: Transgenesis and Targeted Mutagenesis in Immunology, pp. 113-133, Bluethmann H. and Ohashi P. S. (eds), Academic Press, San Diego
69. Speiser D. E., Miranda R., Zakarian A., Bachmann M. F., McKall-Faienza K., Odermatt B. et al. (1997) Self antigens expressed by solid tumors do not stimulate naive or activated T cells: implications for immunotherapy. J. Exp. Med. 186: 645-653
70. Hanahan D. (1985) Heritable formation of pancreatic β-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature 315: 115-122
71. Ohashi P. S., Oehen S., Bürki K., Pircher H., Ohashi C. T., Odermatt B. et al. (1991) Ablation of 'tolerance' and induction of diabetes by virus infection in viral antigen transgenic mice. Cell 65: 305-317
72. Oldstone M. B. A., Nerenberg M., Southern P., Price J. and Lewicki H. (1991) Virus infection triggers insulin-dependent diabetes mellitus in a transgenic model: role of anti-self (virus) immune response. Cell 65: 319-331
73. Ohashi P. S., Oehen S., Aichele P., Pircher H., Odermatt B., Herrera P. et al. (1993) Induction of diabetes is influenced by the infectious virus and local expression of MHC class I and TNF-α. J. Immunol. 150: 5185-5194
74. Leach D. R., Krummel M. F. and Allison J. P. (1996) Enhancement of antitumor immunity by CTLA-4 blockade. Science 271: 1734-1736
75. Naughton G. K., Eisinger M. and Bystryn J. C. (1983) Autoantibodies to normal human melanocytes in vitiligo. J. Exp. Med. 158: 246-251
76. Song Y.-H., Conner E., Li Y., Zorovich B., Balducci P. and Maclaren N. (1994) The role of tyrosinase in autoimmune vitiligo. Lancet 344: 1049-1052
77. Visseren M. J. W., van Elsas A., van der Voort E. J. H., Ressing M. E., Kast W. M., Schrier P. I. et al. (1995) CTL specific for the tyrosinase autoantigen can be induced from healthy donor blood to lyse melanoma cells. J. Immunol. 154: 3991-3998
78. Hara I., Takechi Y. and Houghton A. N. (1995) Implicating a role for immune recognition of self in tumor rejection: immunizution against the brown locus protein. J. Exp. Med. 182: 1609-1614
79. Livingston P. O., Wong G. Y. C. and Adluri S. (1994) Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J. Clin. Invest. 12: 1036-1044
80. Jones P. C., Sze L. L., Liu P. Y., Morron D. L. and Irje R. E. (1981) Prolonged survival for melanoma patients with elevated IgM antibody to oncoferol antigen. J. Natl. Cancer Inst. 66: 249-254
81. Nordlund J. J., Kirkwood J. M., Forget B. M., Milton G., Albert D. M. and Lerner A. B. (1983) Vitiligo in patients with metastatic melanoma: a good prognostic sign. J. Am. Acad. Derm. 9: 689-695
82. Kawakami Y., Eliyahu S., Delgado C. H., Robbins P. F., Sakaguchi K., Appella E. et al. (1994) Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc. Natl. Acad. Sci. USA 91: 6458-6462
83. Hu J., Kindsvogel W., Busby S., Bailey M. C., Shi Y.-Y. and Greenberg P. D. (1991) An evaluation of the potential to use tumor-associated antigens as targets for antitumor T cell therapy using transgenic mice expressing a retroviral tumor antigen in normal lymphoid tissues. J. Exp. Med. 177: 1681-1690
84. Vierboom M. P. M., Nijman H. W., Offringa R., van der Voort E. I. H., van Hall T., van den Broek L. et al. (1997) Tumor eradication by wild-type p53 specific cytotoxic T lymphocytes. J. Exp. Med. 186: 695-704
85. Mitchell M. S., Kan-Mitchell J., Kempf R. A., Harel W., Shau, H. Y. and Lind S. (1988) Active specific immunotherapy for melanoma: phase I trial of allogeneic lysates and a novel adjuvant. Cancer Res. 48: 5883-5893
86. Fendly B. M., Kotts C., Wong W. L. T., Figari I., Harel W., Staib L. et al. (1993) Vaccine Res. 2: 129-139
87. Disis M. L. and Cheever M. A. (1996) Oncogenic proteins as tumor antigens. Curr. Opin. Immunol. 8: 637-642
88. Tindle R. W. (1996) Human papillomavirus vaccines for cervical cancer. Curr. Opin. Immunol. 8: 643-650
89. Melief C. J. M., Offringa R., Toes R. E. M. and Kast W. M. (1996) Peptide-based cancer vaccines. Curr. Opin. Immunol. 8: 651-657
90. Taylor J., Weinberg R., Tartaglia L. A., Richardson C. D., Alkhatib G., Briedis D. et al. (1992) Nonreplicating viral vectors as potential vaccines: recombinant canarypox virus expressing measles virus fusion (F) and hemagglutinin (HA) glyco-proteins. Virology 187: 321-328
91. Restifo N. P. (1996) The new vaccines: building viruses that elicit antitumor immunity. Curr. Opin. Immunol. 8: 658-663
92. Huang A., Golumbek P., Ahmadzadeh M., Jaffee E. M., Pardoll D. and Fevitsky H. I. (1994) Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 264: 961-965
93. Porgador A., Snyder D. and Gilboa F. (1996) Induction of antitumor immunity using bone marrow-generated dendritic cells. J. Immunol. 156: 2918-2926
94. Young J. W. and Inaba K. (1996) Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity. J. Exp. Med. 183: 7-11
95. Paglia P., Chiodoni C., Rodolfo M. and Colombo M. P. (1996) Murine dendritic cells loaded in vitro with soluble protein prime CTF against tumor antigen in vivo. J. Exp. Med. 183: 317-322
96. Celluzzi C. M., Mayordomo J. I., Storkus W. J., Fotze M. T. and Falo Jr L. D. (1996) Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J. Exp. Med. 183: 283-287
97. Zitvogel L., Mayordomo J. I., Tjandrawan T., DeLeo A. B., Clarke M. R., Fotze M. T. et al. (1996) Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation and T helper cell 1-associated cytokines. J. Exp. Med. 183: 87-97
98. Aggarwal A., Kumar S., Jaffe R., Hone D., Gross M. and Sadoff, J. (1990) Oral Salmonella: malaria circumsporozoite recombinants induce specific CD8+ cytotoxic T cells. J. Exp. Med. 172: 1083-1090
99. Stover C. K., De la Cruz V. F., Fuerst T. R., Burlein J. E., Benson L. A., Bennett L. T. et al. (1991) New use of BCG for recombinant vaccines. Nature 351: 456-460
100. Greenberg P. D. and Riddell S. R. (1992) Tumor-specific T-cell immunity: ready for prime time. J. Natl. Cancer Inst. 84: 1059-1061
101. Sosman J. A. and Sondel P. M. (1987) The graft-versus-leukemia effect following bone marrow transplantation. A review of laboratory and clinical data. Hematol. Rev. 2: 77-87
102. Porter D. L., Roth M. S., McGarigle C., Ferrara, J. L. and Antin J. H. (1994) Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N. Engl. J. Med. 330: 100-106
103. Baskar S., Ostrand-Rosenberg S., Nabavi N., Nadler L. M., Freeman G. J. and Glimcher L. H. (1993) Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules. Proc. Natl. Acad. Sci. USA 90: 5687-5690